Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a report released on Saturday. The firm set a “hold” rating on the stock.

CTLT has been the topic of a number of other research reports. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $63.40.

Catalent Price Performance

CTLT stock opened at $63.48 on Friday. The firm has a 50-day moving average price of $61.27 and a 200-day moving average price of $59.84. Catalent has a 12 month low of $41.15 and a 12 month high of $63.50. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $11.52 billion, a P/E ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) EPS. As a group, equities research analysts anticipate that Catalent will post 0.78 EPS for the current fiscal year.

Insider Buying and Selling at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Hedge funds have recently bought and sold shares of the company. Brooklyn Investment Group bought a new stake in Catalent in the third quarter worth approximately $31,000. Sentry Investment Management LLC bought a new stake in shares of Catalent in the 3rd quarter valued at $53,000. Longfellow Investment Management Co. LLC lifted its position in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares during the period. Thurston Springer Miller Herd & Titak Inc. boosted its stake in Catalent by 57.5% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in Catalent in the third quarter worth $73,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.